|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
2782.00
|
|
|
52-Week-Low (Rs.)
|
1599.00
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 21,230.00 | 21,460.00 | 21,210.00 | 19,200.00 | Total Expenditure | 14,220.00 | 14,100.00 | 13,840.00 | 13,420.00 | PBIDT (Excl OI) | 7,010.00 | 7,360.00 | 7,370.00 | 5,780.00 | Other Income | -110.00 | 150.00 | 110.00 | 260.00 | Operating Profit | 6,900.00 | 7,510.00 | 7,480.00 | 6,040.00 | Interest | 690.00 | 770.00 | 900.00 | 940.00 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 6,210.00 | 6,740.00 | 6,580.00 | 5,100.00 | Depreciation | 1,910.00 | 1,920.00 | 1,830.00 | 1,820.00 | Profit Before Tax | 4,300.00 | 4,820.00 | 4,750.00 | 3,280.00 | Tax | 1,330.00 | 1,550.00 | 1,520.00 | 1,090.00 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 2,970.00 | 3,270.00 | 3,230.00 | 2,190.00 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 2,970.00 | 3,270.00 | 3,230.00 | 2,190.00 | Equity Capital | 1,692.30 | 1,692.30 | 1,692.30 | 1,692.30 | Face Value (IN RS) | 5 | 5 | 5 | 5 | Reserves | | | | | Calculated EPS | 8.78 | 9.66 | 9.54 | 6.47 | Calculated EPS (Annualised) | 35.10 | 38.65 | 38.17 | 25.88 | No of Public Share Holdings | 97,316,000.00 | 97,316,000.00 | 97,316,000.00 | 97,316,000.00 | % of Public Share Holdings | 28.75 | 28.75 | 28.75 | 28.75 | | | | | | PBIDTM% (Excl OI) | 33.02 | 34.30 | 34.75 | 30.10 | PBIDTM% | 32.50 | 35.00 | 35.27 | 31.46 | PBDTM% | 29.25 | 31.41 | 31.02 | 26.56 | PBTM% | 20.25 | 22.46 | 22.40 | 17.08 | PATM% | 13.99 | 15.24 | 15.23 | 11.41 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|